The DOI matches its Crossref record; 171 of the 173 references it cites were found in a registry or an index.
How were new medicines discovered?
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are two main advantages of the phenotypic screening method for identifying covalent PPI inhibitors. Firstly, this technique identifies cell-active compounds directly. Secondly, the biological target does not have to be known before screening [81].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [81]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Enzyme structure and mechanism
Fersht, A. (1977) · Medical Entomology and Zoology · Cited by 2,875
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161 · cited 1×
“The biologics were further categorized according to their pharmacological action as described by Leader, Baca and Gola”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“The functional consequence of these resistance mutations is therefore to enable ATP to compete more effectively with gefitinib and erlotini”
BackgroundMendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (2001) · Chest · doi:10.1378/chest.119.1_suppl.64s · Cited by 1,580
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,554
Photodynamic therapy with endogenous protoporphyrin
Kennedy, J. C., Pottier, R. H., & Pross, D. C. (1990) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/1011-1344(90)85083-9 · Cited by 1,509
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,116
(1991) · PubMed · Cited by 1,101
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Pharmacologic Analysis of Drug Receptor Interaction
Kenakin, K. T. (1988) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198803000-00029 · Cited by 927
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
Roth, G. J., & Majerus, P. W. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108132 · Cited by 861
Molecular Mechanisms of Local Anesthesia: A Review
Butterworth, J. F., & Strichartz, G. R. (1990) · Anesthesiology · doi:10.1097/00000542-199004000-00022 · Cited by 848
Drugs, their targets and the nature and number of drug targets
Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 839
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Lewis, D. A., & Lieberman, J. A. (2000) · Neuron · doi:10.1016/s0896-6273(00)00111-2 · Cited by 811
Gutfreund, H. (1978) · FEBS Letters · doi:10.1016/0014-5793(78)81212-5 · Cited by 759
Integrase inhibitors to treat HIV/Aids
Pommier, Y., Johnson, A. A., & Marchand, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1660 · Cited by 688
Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties
Antzelevitch, C., Belardinelli, L., Zygmunt, A. C., Burashnikov, A., Di Diego, J. M., Fish, J. M., Cordeiro, J. M., & Thomas, G. (2004) · Circulation · doi:10.1161/01.cir.0000139333.83620.5d · Cited by 675
The odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 666
Strategies in the design of antiviral drugs
De Clercq, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd703 · Cited by 652
Choay, J., Petitou, M., Lormeau, J. C., Sinaÿ, P., Casu, B., & Gatti, G. (1983) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(83)90550-8 · Cited by 647
Summa, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M., Fiore, F., Gardelli, C., Gonzalez Paz, O., Hazuda, D. J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800245z · Cited by 633
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Kenakin, T., & Miller, L. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.108.000992 · Cited by 573
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Chaitman, B. R., Skettino, S. L., Parker, J. O., Hanley, P., Meluzin, J., Kuch, J., Pepine, C. J., Wang, W., Nelson, J. J., Hebert, D. A., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.045 · Cited by 567
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
Tummino, P. J., & Copeland, R. A. (2008) · Biochemistry · doi:10.1021/bi8002023 · Cited by 544
Structure-based design of aliskiren, a novel orally effective renin inhibitor
Wood, J. M., Maibaum, J., Rahuel, J., Grütter, M. G., Cohen, N.-C., Rasetti, V., Rüger, H., Göschke, R., Stutz, S., Fuhrer, W., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01451-7 · Cited by 506
Probing the links between in vitro potency, ADMET and physicochemical parameters
Gleeson, M. P., Hersey, A., Montanari, D., & Overington, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3367 · Cited by 503
Inhibition of the immune response by rapamycin, a new antifungal antibiotic
Martel, R. R., Klicius, J., & Galet, S. (1977) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y77-007 · Cited by 463
N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.
Platt, F. M., Neises, G. R., Dwek, R. A., & Butters, T. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37202-2 · Cited by 455
Drug–target residence time: critical information for lead optimization
Lu, H., & Tonge, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.176 · Cited by 432
Wijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 427
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R. A., & Marks, P. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5705 · Cited by 420
Biochemical mechanisms of drug action: what does it take for success?
Swinney, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1500 · Cited by 394
Self-citationFRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent
Stenoien, D. L., Patel, K., Mancini, M. G., Dutertre, M., Smith, C. L., O'Malley, B. W., & Mancini, M. A. (2001) · Nature Cell Biology · doi:10.1038/35050515 · Cited by 393
Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
Non-peptide arginine-vasopressin antagonists: the vaptans
Decaux, G., Soupart, A., & Vassart, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60695-9 · Cited by 376
Wacker, D., Fenalti, G., Brown, M. A., Katritch, V., Abagyan, R., Cherezov, V., & Stevens, R. C. (2010) · Journal of the American Chemical Society · doi:10.1021/ja105108q · Cited by 358
Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels
Bormann, J. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90385-3 · Cited by 351
Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin
Hadváry, P., Lengsfeld, H., & Wolfer, H. (1988) · Biochemical Journal · doi:10.1042/bj2560357 · Cited by 345
WEIBEL, E. K., HADVARY, P., HOCHULI, E., KUPFER, E., & LENGSFELD, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1081 · Cited by 341
Diverse mechanisms of antiepileptic drugs in the development pipeline
Rogawski, M. A. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.02.004 · Cited by 340
Lindsay, M. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1202 · Cited by 332
Development of daptomycin for Gram-positive infections
Tally, F. P., & DeBruin, M. F. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.4.523 · Cited by 321
Wilson, D. N., Schluenzen, F., Harms, J. M., Starosta, A. L., Connell, S. R., & Fucini, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804276105 · Cited by 318
HIV drug development: the next 25 years
Flexner, C. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2336 · Cited by 317
Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317 · cited 1×
“For example, the HIV1 integrase inhibitor raltegravir was only discovered after several MMOAs had been investigated using different assay format”
BackgroundTetrahydrobiopterin as an Alternative Treatment for Mild Phenylketonuria
Muntau, A. C., Röschinger, W., Habich, M., Demmelmair, H., Hoffmann, B., Sommerhoff, C. P., & Roscher, A. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021654 · Cited by 311
New thrombopoietic growth factors
Kuter, D. J. (2007) · Blood · doi:10.1182/blood-2006-10-019315 · Cited by 307
Watson, C., Jenkinson, S., Kazmierski, W., & Kenakin, T. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008565 · Cited by 302
Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency
Kure, S., Hou, D.-C., Ohura, T., Iwamoto, H., Suzuki, S., Sugiyama, N., Sakamoto, O., Fujii, K., Matsubara, Y., & Narisawa, K. (1999) · The Journal of Pediatrics · doi:10.1016/s0022-3476(99)70138-1 · Cited by 299
Therapeutic Strategies Based on Glucagon-Like Peptide 1
Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296
Pharmacologic analysis of drug-receptor interaction
Short, A. L. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)90240-6 · Cited by 290
New Thrombopoietic Growth Factors
Kuter, D. J. (2009) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2009.s.034 · Cited by 285
Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10600-9 · Cited by 276
Tiotropium (SPIRIVA™): Mechanistical considerations and clinical profile in obstructive lung disease
Disse, B., Speck, G. A., Rominger, K. L., Witek, T. J., & Hammer, R. (1999) · Life Sciences · doi:10.1016/s0024-3205(98)00588-8 · Cited by 274
Pathologically activated therapeutics for neuroprotection
Lipton, S. A. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2229 · Cited by 257
Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency
Shintaku, H., Kure, S., Ohura, T., Okano, Y., Ohwada, M., Sugiyama, N., Sakura, N., Yoshida, I., Yoshino, M., Matsubara, Y., et al. (2005) · Zhongguo dangdai erke zazhi · Cited by 254
Valentino, K., Newcomb, R., Gadbois, T., Singh, T., Bowersox, S., Bitner, S., Justice, A., Yamashiro, D., Hoffman, B. B., & Ciaranello, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7894 · Cited by 249
SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents
Cuppoletti, J., Malinowska, D. H., Tewari, K. P., Li, Q.-J., Sherry, A. M., Patchen, M. L., & Ueno, R. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00528.2003 · Cited by 232
ucb L059, a novel anti-convulsant drug: pharmacological profile in animais
Gower, A. J., Noyer, M., Verloes, R., Gobert, J., & Wülfert, E. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90855-x · Cited by 212
Mechanism of action of the oxazolidinone antibacterial agents
Shinabarger, D. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.8.1195 · Cited by 211
Role of Induced Fit in Enzyme Specificity: A Molecular Forward/Reverse Switch
Johnson, K. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800034200 · Cited by 204
Blau, N., & Erlandsen, H. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.03.006 · Cited by 194
Pincus, G. (1965) · Cited by 187
Boismare, F., Daoust, M., Moore, N., Saligaut, C., Lhuintre, J. P., Chretien, P., & Durlach, J. (1984) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(84)80020-9 · Cited by 184
The beautiful cell: high-content screening in drug discovery
Bickle, M. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3788-3 · Cited by 176
Oxazolidinone Antibacterial Agents
Brickner, S. J. (1996) · Current Pharmaceutical Design · doi:10.2174/1381612802666220921173820 · Cited by 171
Mifepristone (RU486): A review
Mahajan, D. K., & London, S. N. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00189-1 · Cited by 164
Issa, J. J., Kantarjian, H. M., & Kirkpatrick, P. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1698 · Cited by 163
Preliminary Studies on a More Effective Phototoxic Agent Than Hematoporphyrin
Richter, A. M., Kelly, B. S., Chow, J., Liu, D. J., Towers, G. H. N., Dolphin, D., & Levy, J. G. (1987) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/79.6.1327 · Cited by 161
New therapeutics that antagonize endothelin: promises and frustrations
Remuzzi, G., Perico, N., & Benigni, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd962 · Cited by 160
Vigilance and Validation: Keys to Success in RNAi Screening
Sigoillot, F. D., & King, R. W. (2010) · ACS Chemical Biology · doi:10.1021/cb100358f · Cited by 144
Oshiro, Y., Sato, S., Kurahashi, N., Tanaka, T., Kikuchi, T., Tottori, K., Uwahodo, Y., & Nishi, T. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm940608g · Cited by 143
Synthesis of a Novel Series of Tricyclic Indan Derivatives as Melatonin Receptor Agonists
Uchikawa, O., FUKATSU, K., Tokunoh, R., Kawada, M., Matsumoto, K., Imai, Y., Hinuma, S., Kato, K., Nishikawa, H., Hirai, K., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0201159 · Cited by 143
Hemphill, A. F., Mueller, J., & Esposito, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.7.953 · Cited by 142
The Adamantyl Group in Medicinal Agents. I. Hypoglycemic N-Arylsulfonyl-N'-adamantylureas
Gerzon, K., Krumkalns, E. V., Brindle, R. L., Marshall, F. J., & Root, M. A. (1963) · Journal of Medicinal Chemistry · doi:10.1021/jm00342a029 · Cited by 142
Brownlee, J. M., Johnson-Winters, K. L., Harrison, D. H. T., & Moran, G. R. (2004) · Biochemistry · doi:10.1021/bi049317s · Cited by 136
Nitazoxanide in the Treatment of Taenia Saginata and Hymenolepis nana Infections
Rossignol, J., & Maisonneuve, H. (1984) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1984.33.511 · Cited by 133
Regio and stereospecific synthesis of 11β-substituted 19-norsteroids
Bèlanger, A., Philibert, D., & Teutsch, G. (1981) · Steroids · doi:10.1016/0039-128x(81)90039-8 · Cited by 132
Hu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., & Boettcher, B. R. (2000) · PubMed · Cited by 126
Echinocandin inhibition of 1,3‐β‐D‐glucan synthase from Candida albicans
Sawistowska-Schröder, E. T., Kerridge, D., & Perry, H. (1984) · FEBS Letters · doi:10.1016/0014-5793(84)81032-7 · Cited by 124
Allosteric Receptors: From Electric Organ to Cognition
Changeux, J. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105741 · Cited by 122
Anthes, J. C., Gilchrest, H., Richard, C., Eckel, S. P., Hesk, D., West, R. E., Williams, S. M., Greenfeder, S. A., Billah, M. M., Kreutner, W., et al. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02049-6 · Cited by 121
Lichtner, R. B., Menrad, A., Sommer, A., Klar, U., & Schneider, M. R. (2001) · PubMed · Cited by 121
Dopamine receptor agonists, partial agonists and psychostimulant addiction
Pulvirenti, L., & Koob, G. F. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90158-9 · Cited by 114
Lock, E. A., Ellis, M. K., Gaskin, P., Robinson, M., Auton, T. R., Provan, W. M., Smith, L. L., Prisbylla, M. P., Mutter, L. C., & Lee, D. L. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005458703363 · Cited by 109
Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex.
Katz, D. H., Marcelletti, J. F., Khalil, M., Pope, L. E., & Katz, L. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10825 · Cited by 109
Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461
Salisbury, B. G., Davis, H. R., Burrier, R. E., Burnett, D. A., Boykow, G. C., Caplen, M. A., Clemmons, A., Compton, D. S., Hoos, L. M., McGregor, D. G., et al. (1995) · Atherosclerosis · doi:10.1016/0021-9150(94)05499-9 · Cited by 107
Maibaum, J., Stutz, S., Göschke, R., Rigollier, P., Yamaguchi, Y., Cumin, F., Rahuel, J., Baum, H.-P., Cohen, N.-C., Schnell, C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070316i · Cited by 98
Swinney, D. C. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743093 · Cited by 97
Self-citation2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.
Lambe, C. U., Averett, D. R., Paff, M. T., Reardon, J. E., Wilson, J. G., & Krenitsky, T. A. (1995) · PubMed · Cited by 93
Bartizal, K. F., Abruzzo, G. K., Trainor, C., Krupa, D. A., Nollstadt, K. H., Schmatz, D. M., Schwartz, R., Hammond, M. L., Balkovec, J. M., & VanMiddlesworth, F. L. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.8.1648 · Cited by 93
Designing transient binding drugs: A new concept for drug discovery
Ohlson, S. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.02.001 · Cited by 93
Competitiveness in follow-on drug R&D: a race or imitation?
DiMasi, J. A., & Faden, L. B. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3296 · Cited by 93
Inoue, T., Domae, M., Yamada, K., & Furukawa, T. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12799-7 · Cited by 92
Peña-Munzenmayer, G., Catalán, M., Cornejo, I., Figueroa, C., Melvin, J., Niemeyer, M., Cid, L., & Sepúlveda, F. (2005) · Journal of Cell Science · doi:10.1242/jcs.02525 · Cited by 91
Shinkai, H., Nishikawa, M., Sato, Y., Toi, K., Kumashiro, I., Seto, Y., Fukuma, M., Dan, K., & Toyoshima, S. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00127a006 · Cited by 83
Mechanisms for T-cell selective cytotoxicity of arabinosylguanine
Rodriguez, C. O., Stellrecht, C. M., & Gandhi, V. V. (2003) · Blood · doi:10.1182/blood-2003-01-0317 · Cited by 82
Swinney, D. C. (2008) · Pharmaceutical Medicine · doi:10.1007/bf03256679 · Cited by 79
Self-citationHu, S., Wang, S., Fanelli, B., Bell, P. A., Dunning, B. E., Geisse, S., Schmitz, R., & Boettcher, B. R. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39254-7 · Cited by 78
Yanagihara, Y., Kasai, H., KAWASHIMA, T., & Shida, T. (1988) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.48.91 · Cited by 77
Verteporfin: a milestone in opthalmology and photodynamic therapy
Mellish, K. J., & Brown, S. B. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.2.351 · Cited by 77
3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile.
Masuda, Y., Karasawa, T., Shiraishi, Y., Hori, M., Yoshida, K., & Shimizu, M. S. (1980) · PubMed · Cited by 73
Experimental Porphyric Neuropathy: A Preliminary Report
Sima, A. A. F., Kennedy, J. C., Blakeslee, D., & Robertson, D. M. (1981) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100042992 · Cited by 72
N-Acylphenylalanines and related compounds. A new class of oral hypoglycemic agents
Shinkai, H., Toi, K., Kumashiro, I., Seto, Y., Fukuma, M., Dan, K., & Toyoshima, S. (1988) · Journal of Medicinal Chemistry · doi:10.1021/jm00119a007 · Cited by 71
Hunt, E. (2000) · Drugs of the Future · doi:10.1358/dof.2000.025.11.858699 · Cited by 71
Raaijmakers, H. C. A., Versteegh, J. E., & Uitdehaag, J. C. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.007872 · Cited by 68
Kavana, M., & Moran, G. R. (2003) · Biochemistry · doi:10.1021/bi034658b · Cited by 68
Sands, J. A., Auperin, D. D., & Snipes, W. (1979) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.15.1.67 · Cited by 67
Hanck, D. A., Nikitina, E., McNulty, M. M., Fozzard, H. A., Lipkind, G. M., & Sheets, M. F. (2009) · Circulation Research · doi:10.1161/circresaha.109.198572 · Cited by 65
Chemokine Antagonists as Therapeutics: Focus on HIV-1
Tsibris, A. M. N., & Kuritzkes, D. R. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.58.080105.102908 · Cited by 64
An enzymic synthesis of purine d-Arabinonucleosides
Krenitsky, T. A., Koszalka, G. W., Tuttle, J. V., Rideout, J. L., & Elion, G. B. (1981) · Carbohydrate Research · doi:10.1016/s0008-6215(00)80531-5 · Cited by 63
Green tea catechins for treatment of external genital warts
Meltzer, S. M., Monk, B. J., & Tewari, K. S. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.07.064 · Cited by 61
Pastores, G. M., & Barnett, N. L. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.2.273 · Cited by 59
Neurokinin 1 receptor antagonists--current prospects.
Alvaro, G. S., & Fabio, R. D. (2007) · PubMed · Cited by 53
THE INACTIVATION OF THE VIRUS OF EPIDEMIC INFLUENZA BY SOAPS
Stock, C. C., & Francis, T. (1940) · The Journal of Experimental Medicine · doi:10.1084/jem.71.5.661 · Cited by 53
Purine nucleoside antimetabolites in development for the treatment of cancer.
Wb, P., Ja, S., & Waud, W. R. (2004) · PubMed · Cited by 53
Kendell, R. E. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.176.1.6 · Cited by 51
Gandhi, V. V., Keating, M. J., Bate, G., & Kirkpatrick, P. N. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1933 · Cited by 49
Inactivation of Lipid-Containing Viruses by Long-Chain Alcohols
Snipes, W., Person, S., Keller, G. S., Taylor, W., & Keith, A. D. (1977) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.11.1.98 · Cited by 44
Vauquelin, G., Fierens, F. L. P., & Liefde, I. V. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000220403.61493.18 · Cited by 43
Innovations and Challenges in Renal Cancer
Atkins, M. B., Avigan, D., Bukowski, R. M., Childs, R. W., Dutcher, J. P., Eisen, T. G., Figlin, R. A., Finke, J. H., Flanigan, R. C., George, D. J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040720 · Cited by 41
Misconceptions About Calcimimetics
Nemeth, E. F. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.044 · Cited by 36
Yasuda, Y. U., Kikuchi, T., Suzuki, S., Tsutsui, M., Yamada, K., & Hiyama, T. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90493-6 · Cited by 34
Palchaudhuri, R., & Hergenrother, P. J. (2010) · ACS Chemical Biology · doi:10.1021/cb100310h · Cited by 31
Diseases of Amino Acid Metabolism
Yudkoff, M. (1999) · Cited by 30
Buysse, D. J., Bate, G., & Kirkpatrick, P. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1881 · Cited by 30
Williams, M. J. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.08.019 · Cited by 29
Comparative Pharmacodynamics and Pharmacokinetics of Candesartan and Losartan in Man
Fuchs, B., Breithaupt‐Grögler, K., Belz, G. G., Roll, S., Malerczyk, C., Herrmann, V., Spahn-Langguth, H., & Mutschler, E. (2000) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357001774994 · Cited by 29
Jain, K. K. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.4.829 · Cited by 28
Raloxifene: Magic bullet for heart and bone?
Gustafsson, J.-Α. (1998) · Nature Medicine · doi:10.1038/nm0298-152 · Cited by 26
Pruss, R. M. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710793237377 · Cited by 25
Nishi, T., YAMAMOTO, K., Shimizu, T., Kanbe, T., Kimura, Y., & NAKAGAWA, K. (1983) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.31.798 · Cited by 25
Rethinking Target Discovery in Polygenic Diseases
Flordellis, C. S., Manolis, A. S., Paris, H., & Karabinis, A. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606778194226 · Cited by 19
Ranolazine, a Novel Agent for Chronic Stable Angina
Gaffney, S. M. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2006.26.1.135 · Cited by 16
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.
Walenga, J. M., Fareed, J., Jeske, W. P., Bick, R. L., & Samama, M. M. (2002) · PubMed · Cited by 13
Introduction to the Proteasome and its Inhibitors
Goldberg, A. L. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-794-9_2 · Cited by 7
Vauquelin, G., Fierens, F. L. P., & Liefde, I. V. (2006) · VUBIR (Vrije Universiteit Brussel) · Cited by 6
Research works printed but not linked: 3
- Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
- Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
- Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Cited by
Small-Molecule Library Screening by Docking with PyRx
Dallakyan, S., & Olson, A. J. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2269-7_19 · Cited by 3,998
Discovery and resupply of pharmacologically active plant-derived natural products: A review
Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E.-M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E. H., et al. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.08.001 · Cited by 2,904
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
From 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834
Metadata
- Authors
- Swinney, D. C., & Anthony, J.
- Corresponding author
- Swinney, David C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-06-24
- Volume
- 10
- Issue
- 7
- Pages
- 507-519
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2052214665
- Cited by
- 1,812
- References
- 173
- Citations by year
- 2026: 80 · 2025: 73 · 2024: 102 · 2023: 86 · 2022: 96 · 2021: 109 · 2020: 127 · 2019: 129 · 2018: 113 · 2017: 136 · 2016: 160 · 2015: 170 · 2014: 157 · 2013: 137 · 2012: 115
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug discovery strategies, phenotypic screening, target-based screening, molecular mechanisms of action, first-in-class drugs, new chemical entities, small molecule drugs, drug attrition, FDA-approved drugs
- MeSH terms
- Pharmacological Phenomena, Drug Industry, Drug Evaluation, Preclinical, Humans, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.